Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625885 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL13956844 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL24366649 | 0.90 | CHRM2 (0.41) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL15017885 | 0.90 | CHRM2 (0.41) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL11917895 | 0.89 | CHRM2 (0.41) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL24366554 | 0.86 | CHRM2 (0.47) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL483259 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL20406585 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL11917918 | 0.81 | CHRM2 (0.42) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL4174747 | 0.80 | ACE (0.49) | CHRM2CHRM1CHRM3ELANEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4525987-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-115490708-B | Sulfonamide macrocyclic derivative, preparation method and application thereof | 苏州亚盛药业有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3889138-B1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-115490708-A | Sulfonamide macrocyclic derivatives, and preparation method and application thereof | 苏州亚盛药业有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-25 | — | — | US | disclosed |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8741837-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2028186-A2 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-02-25 | — | — | EP | disclosed |
| WO-2006020664-A2 | AMMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR DPP IV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CHRM2 4873/4885CHRM1 4865/4885CHRM3 4703/4885 |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CHRM2 4873/4885CHRM1 4865/4885CHRM3 4703/4885 |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | IL17A, IL15, IL18 | CHRM2 4776/4885CHRM1 4592/4885CHRM3 4851/4885 |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CHRM2 4873/4885CHRM1 4865/4885CHRM3 4703/4885 |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CHRM2 4873/4885CHRM1 4865/4885CHRM3 4703/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CHRM2 4698/4885CHRM1 4525/4885CHRM3 4278/4885 |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | CHRM2 4152/4885CHRM1 4053/4885CHRM3 4310/4885 |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CHRM2 4873/4885CHRM1 4865/4885CHRM3 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.